The Acquisition
Biomodex specializes in biorealistic 3D printing and flow systems for interventional procedures, with a platform geared towards clinical use and patient-specific simulation. As part of the acquisition,
“Biomodex is truly a quality product company, with experienced staff and a large and highly engaged customer base which is a testament to the value they bring to the market”, said Edward Fält, Chief Strategy Officer ofMentice . “Since its inception in 2015, Biomodex has invested over12 million EUR in IP and R&D, leading to the development of several innovative products and technology advances which will be very synergistic to Mentice’s current portfolio. Thanks to a series of circumstances, we were able to acquire these assets under favorable terms and are now looking forward to taking the business to the next level under the umbrella of the globalMentice organization.”
The acquisition will further consolidate Mentice’s position as the leading provider of virtual, physical and decision-support simulation solutions for image-guided interventional therapies. The acquired assets will add new solutions for neurovascular and structural heart simulation as well as a rapid turn-around production process for direct printing of patient-specific anatomies.
Over the course of 2024,
As an immediate step,
About Biomodex
BIOMODEX® is a Boston and Paris-based medical technology company whose mission is to transform the way physicians train and rehearse procedures. The company 3D prints anatomical models using advanced materials that provide biorealistic haptic feedback. The next-generation biorealistic haptic simulators are fully customizable and integrate with a patented blood flow system and intraprocedural imaging tools such as TEE and ICE, enabling clinicians to gain life-like experience to advance skill sets and promote the adoption of new medical devices or techniques in their pursuit of improving patient outcomes.
© Modular Finance, source